Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial. (2017)
Attributed to:
Establishment of the Cambridge Single Cell Analysis Clinical Core Facility [SCACCF]
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30319-4
PubMed Identifier: 28479233
Publication URI: http://europepmc.org/abstract/MED/28479233
Type: Journal Article/Review
Volume: 18
Parent Publication: The Lancet. Oncology
Issue: 6
ISSN: 1470-2045